Holy Stone Healthcare Co., Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Taipei Taiwan (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2014
NCT02196662
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Holy Stone Healthcare Co., Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Colorectal Neoplasms (Phase 1)

Neoplasms (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 8